Maxim - Model 92003 - 192 Tests HIV-1 Limiting Antigen Avidity (LAg-Avidity) DBS EIA Kit- Brochure

The Maxim HIV-1 Limiting Antigen-Avidity Dried Blood Spot (DBS) EIA is an in-vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Persons with recently acquired HIV-1 infections typically exhibit HIV-1 specific IgG populations with higher proportions of lower avidity IgG than those with long-term infections which typically exhibit higher proportions of higher avidity IgG. The Maxim HIV-1 LAg-Avidity DBS EIA uses US CDC developed technology and is designed for surveillance purposes such as estimating HIV-1 incidence in a population, monitoring and evaluating HIV intervention programs, and recognizing those high-incidence populations so that prevention research, vaccine trials, and resources are most appropriately utilized. This product is for research use only and is not intended for use in diagnostic procedures.